SCHEMBL3623474

SCHEMBL3623474

Cc1ccccc1CC(=O)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 5/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NR1H2 P55055 2/20 0.45
RORC P51449 2/20 0.44
EIF2AK3 Q9NZJ5 1/20 0.43
NR1I2 O75469 1/20 0.42
POLB P06746 2/20 0.42
AVPR1A P37288 1/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
NOTUM Q6P988 1/20 0.41
AVPR2 P30518 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13317307 0.92 MEN1 (0.51) NR1H3MEN1KMT2AEIF2AK3POLB
SCHEMBL3623416 0.90 NR1H3 (0.52) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL15108478 0.89 MEN1 (0.48) NR1H3MEN1KMT2AEIF2AK3POLB
SCHEMBL3626970 0.87 KMT2A (0.66) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL3621272 0.85 NR1H3 (0.58) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL3620198 0.85 NR1H3 (0.49) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL3618184 0.83 POLB (0.49) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL3626626 0.83 MEN1 (0.55) NR1H3MEN1KMT2ANR1H2RORC
SCHEMBL11605696 0.83 NR1H3 (0.54) NR1H3KMT2ANR1H2RORCNR1I2
SCHEMBL3624100 0.82 NR1H3 (0.51) NR1H3MEN1KMT2ANR1H2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951676-B1 N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-07-17 EP disclosed
EP-2392567-A1 BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
EP-1951676-A2 LXR MODULATORS Brystol-Myers Squibb Company (US) 2008-08-06 EP disclosed
WO-2007050425-A2 LXR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-03 WO disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093470-A1 LXR modulators NR1H2, NR1H3, RXRB NR1H3 2/4885MEN1 3861/4885KMT2A 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.